Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,878 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The anticholinergic burden in patients with chronic kidney disease: Patterns, risk factors, and the link with cognitive impairment.
Mouheb A, Levassort H, Massy ZA, Jacquelinet C, Laville M, Alencar de Pinho N, Pépin M, Laville SM, Liabeuf S; Chronic Kidney Disease‐Renal Epidemiology and Information Network (CKD‐REIN) Study Group. Mouheb A, et al. J Am Geriatr Soc. 2024 Nov 28. doi: 10.1111/jgs.19283. Online ahead of print. J Am Geriatr Soc. 2024. PMID: 39605299
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Waldenström Macroglobulinemia.
Durot E, Kanagaratnam L, Zanwar S, Kaufman A, D'Sa S, Toussaint E, Roos-Weil D, Alcoceba M, Vos JMI, Michallet AS, Talaulikar D, Kastritis E, Khwaja J, Treon SP, Garcia-Sanz R, Morel P, Munoz J, Castillo JJ, Kapoor P, Delmer A. Durot E, et al. Among authors: morel p. Am J Hematol. 2024 Nov 26. doi: 10.1002/ajh.27543. Online ahead of print. Am J Hematol. 2024. PMID: 39588555 No abstract available.
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.
Tomowiak C, Poulain S, Nudel M, Feugier P, Herbaux C, Mahé B, Morel P, Aurran T, Tournilhac O, Leprêtre S, Assaad S, Villemagne B, Casasnovas O, Lhermitte A, Roos-Weil D, Torregrosa-Diaz J, Chevret S, Leblond V; on the behalf of the FILO group. Tomowiak C, et al. Among authors: morel p. Ann Hematol. 2024 Nov 5. doi: 10.1007/s00277-024-06076-1. Online ahead of print. Ann Hematol. 2024. PMID: 39499299
1,878 results